Omnicell (OMCL) | Financial Analysis & Statements
Omnicell Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
314.0M
Gross Profit
130.3M
41.51%
Operating Income
415.0K
0.13%
Net Income
-2.0M
-0.65%
EPS (Diluted)
$-0.05
Balance Sheet Metrics
Total Assets
2.0B
Total Liabilities
742.9M
Shareholders Equity
1.2B
Debt to Equity
0.60
Cash Flow Metrics
Operating Cash Flow
32.3M
Free Cash Flow
18.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Omnicell Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.1B | 1.1B | 1.3B | 1.1B |
| Cost of Goods Sold | 681.4M | 641.2M | 650.3M | 707.0M | 577.4M |
| Gross Profit | 503.4M | 471.0M | 496.8M | 589.0M | 554.7M |
| Gross Margin % | 42.5% | 42.3% | 43.3% | 45.4% | 49.0% |
| Operating Expenses | |||||
| Research & Development | 88.7M | 90.4M | 97.1M | 105.0M | 75.7M |
| Selling, General & Administrative | 409.6M | 380.3M | 434.6M | 486.3M | 389.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 498.3M | 470.7M | 531.7M | 591.3M | 465.1M |
| Operating Income | 5.2M | 337.0K | -34.9M | -2.3M | 89.5M |
| Operating Margin % | 0.4% | 0.0% | -3.0% | -0.2% | 7.9% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 11.3M | 25.6M | -20.1M | -2.5M | 66.0M |
| Income Tax | 9.3M | 13.1M | 263.0K | -8.1M | -11.8M |
| Effective Tax Rate % | 81.9% | 51.0% | 0.0% | 0.0% | -17.9% |
| Net Income | 2.1M | 12.5M | -20.4M | 5.6M | 77.8M |
| Net Margin % | 0.2% | 1.1% | -1.8% | 0.4% | 6.9% |
| Key Metrics | |||||
| EBITDA | 91.8M | 90.1M | 60.7M | 96.8M | 174.4M |
| EPS (Basic) | $0.04 | $0.27 | $-0.45 | $0.13 | $1.79 |
| EPS (Diluted) | $0.04 | $0.27 | $-0.45 | $0.12 | $1.62 |
| Basic Shares Outstanding | 45965000 | 46047000 | 45212000 | 44398000 | 43475000 |
| Diluted Shares Outstanding | 45965000 | 46047000 | 45212000 | 44398000 | 43475000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Omnicell Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 196.5M | 369.2M | 468.0M | 330.4M | 349.1M |
| Short-term Investments | 14.6M | 12.5M | 11.9M | 11.5M | 10.7M |
| Accounts Receivable | 216.9M | 256.4M | 252.0M | 299.5M | 240.9M |
| Inventory | 100.9M | 88.7M | 110.1M | 147.5M | 119.9M |
| Other Current Assets | 3.7M | 13.6M | 7.7M | 7.5M | 10.6M |
| Total Current Assets | 680.1M | 815.5M | 927.6M | 881.8M | 780.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 128.4M | 125.3M | 121.0M | 129.4M | 137.8M |
| Goodwill | 1.7B | 1.7B | 1.7B | 1.8B | 1.9B |
| Intangible Assets | 224.3M | 246.7M | 277.8M | 323.7M | 374.6M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 74.3M | 78.3M | 56.7M | 46.6M | 46.4M |
| Total Non-Current Assets | 1.3B | 1.3B | 1.3B | 1.3B | 1.4B |
| Total Assets | 2.0B | 2.1B | 2.2B | 2.2B | 2.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 44.0M | 51.8M | 45.0M | 63.4M | 71.5M |
| Short-term Debt | 12.0M | 185.0M | 10.5M | 10.8M | 501.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 476.6M | 595.7M | 367.8M | 428.4M | 876.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 192.4M | 197.5M | 603.6M | 606.0M | 39.9M |
| Deferred Tax Liabilities | 683.0K | 1.1M | 1.6M | 2.1M | 51.7M |
| Other Non-Current Liabilities | 10.0M | 7.2M | 6.3M | 6.7M | 7.8M |
| Total Non-Current Liabilities | 266.3M | 282.0M | 670.1M | 652.2M | 119.6M |
| Total Liabilities | 742.9M | 877.6M | 1.0B | 1.1B | 995.8M |
| Equity | |||||
| Common Stock | 58.0K | 57.0K | 56.0K | 55.0K | 54.0K |
| Retained Earnings | 384.9M | 382.9M | 370.4M | 390.7M | 368.6M |
| Treasury Stock | 368.3M | 290.3M | 290.3M | 290.3M | 238.1M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.2B | 1.2B | 1.2B | 1.1B | 1.1B |
| Key Metrics | |||||
| Total Debt | 204.3M | 382.5M | 614.1M | 616.7M | 541.0M |
| Working Capital | 203.5M | 219.8M | 559.8M | 453.4M | -95.5M |
Balance Sheet Composition
Omnicell Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.1M | 12.5M | -20.4M | 5.6M | 77.8M |
| Depreciation & Amortization | 86.6M | 89.8M | 95.6M | 99.2M | 84.9M |
| Stock-Based Compensation | 44.5M | 39.3M | 55.3M | 68.2M | 53.2M |
| Working Capital Changes | 20.6M | 38.1M | 67.3M | -92.2M | -38.0M |
| Operating Cash Flow | 155.1M | 168.6M | 191.1M | 47.7M | 196.8M |
| Investing Activities | |||||
| Capital Expenditures | -40.4M | -36.5M | -41.5M | -47.5M | -29.0M |
| Acquisitions | - | 0 | 0 | 2.1M | -354.2M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -42.8M | -36.5M | -41.5M | -45.5M | -383.1M |
| Financing Activities | |||||
| Share Repurchases | -77.6M | 0 | 0 | -52.2M | 0 |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 166.3M | - | 0 | 0 |
| Debt Repayment | -175.0M | -391.7M | - | 0 | 0 |
| Financing Cash Flow | -235.2M | -274.2M | 204.0K | -61.1M | -20.0M |
| Free Cash Flow | 69.4M | 134.9M | 126.1M | 17.0M | 173.5M |
| Net Change in Cash | -122.9M | -142.0M | 149.8M | -58.9M | -206.4M |
Cash Flow Trend
Omnicell Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
918.75
Forward P/E
17.60
Price to Book
1.34
Price to Sales
1.41
PEG Ratio
-8.01
Profitability Ratios
Profit Margin
0.17%
Operating Margin
2.20%
Return on Equity
0.17%
Return on Assets
0.36%
Financial Health
Current Ratio
1.43
Debt to Equity
16.59
Beta
0.86
Per Share Data
EPS (TTM)
$0.04
Book Value per Share
$27.36
Revenue per Share
$25.78
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| OMCL | 1.7B | 918.75 | 1.34 | 0.17% | 0.17% | 16.59 |
| Ge Healthcare | 31.9B | 15.92 | 3.18 | 22.38% | 10.10% | 98.72 |
| Veeva Systems | 26.5B | 29.57 | 3.66 | 13.93% | 28.45% | 1.33 |
| Teladoc Health | 1.0B | - | 0.74 | -13.93% | -7.92% | 75.06 |
| Certara | 969.0M | 105.00 | 0.95 | -0.15% | -0.38% | 28.96 |
| Schrodinger | 870.4M | 44.39 | 2.39 | -26.29% | -40.36% | 30.03 |
Financial data is updated regularly. All figures are in the company's reporting currency.






